1. Home
  2. > Healthcare
  3. > Pathology Market Trends
JAKAFI Drug Insight and Market Forecast – 2032

JAKAFI Drug Insight and Market Forecast – 2032

  • September 2022
  • 30 pages
  • ID: 6321471
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“JAKAFI Drug Insight and Market Forecast – 2032” report provides comprehensive insights about JAKAFI for Polycythemia Vera in the 7MM. A detailed picture of the JAKAFI for Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the JAKAFI for Polycythemia Vera. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JAKAFI market forecast, analysis for Polycythemia Vera in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Polycythemia Vera.

Drug Summary
Jakafi is a kinase inhibitor developed by Incyte Corporationand and Novartis, designated for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis, post-polycythemia Vera (PV) myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. This drug is also approved for adult patients of PV who have had a poor response to hydroxyurea.
Polycythemia Vera is myeloproliferative neoplasms (MPN) known to be associated with dysregulated JAK1 and JAK2 signaling. Jakafi is a kinase inhibitor that specifically inhibits JAK1 and JAK2, which mediate the signaling of several cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves the recruitment of transcription factor STATs (signal transducers and activators of transcription) to cytokine receptors. It activates and subsequent localization of STATs to the nucleus leading to modulation of gene expression.
The recommended starting dose of Jakafi in PV is 10 mg given orally twice daily. There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and <100,000/mm3. The maximum recommended starting dose in these patients is 5 mg twice daily, and the patients must be titrated cautiously.
Jakafi is also approved for treating steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Some trials of the ruxolitinib are still ongoing in Phase III and Phase II clinical trials for the treatment of PV.

Scope of the Report
The report provides insights into:
• A comprehensive product overview including the JAKAFI description, mechanism of action, dosage and administration, research and development activities in Polycythemia Vera.
• Elaborated details on JAKAFI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JAKAFI research and development activity in Polycythemia Vera details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around JAKAFI.
• The report contains forecasted sales of JAKAFI for Polycythemia Vera till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Polycythemia Vera.
• The report also features the SWOT analysis with analyst views for JAKAFI in Polycythemia Vera.

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JAKAFI Analytical Perspective
• In-depth JAKAFI Market Assessment
This report provides a detailed market assessment of JAKAFI in Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• JAKAFI Clinical Assessment
The report provides the clinical trials information of JAKAFI for Polycythemia Vera covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights
• In the coming years, the market scenario for Polycythemia Vera is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JAKAFI dominance.
• Other emerging products for Polycythemia Vera are expected to give tough market competition to JAKAFI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JAKAFI in Polycythemia Vera.
• Our in-depth analysis of the forecasted sales data of JAKAFI from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JAKAFI in Polycythemia Vera.

Key Questions
• What is the product type, route of administration and mechanism of action of JAKAFI?
• What is the clinical trial status of the study related to JAKAFI in Polycythemia Vera and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JAKAFI development?
• What are the key designations that have been granted to JAKAFI for Polycythemia Vera?
• What is the forecasted market scenario of JAKAFI for Polycythemia Vera?
• What are the forecasted sales of JAKAFI in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Polycythemia Vera and how are they giving competition to JAKAFI for Polycythemia Vera?
• Which are the late-stage emerging therapies under development for the treatment of Polycythemia Vera?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on